MTOR and angiomyolipoma: Table 2 summarizes safety data from phase 2 and 3 studies of the mTOR inhibitors in patients with advanced metastatic sarcomas (temsirolimus, ridaforolimus), imatinib-resistant GIST (everolimus in combination with imatinib), or angiomyolipomas (sirolimus).85-89 The most common AEs reported for at least 2 mTOR inhibitors include mouth ulcers (characterized as apthous ulcers, mucositis, or stomatitis), diarrhea, fatigue, anemia, and nausea.